Anandamide-d8

Anandamide-d8

• CAS Number: 924894-98-4
• UNSPSC Description: Anandamide-d8 is a deuterated labeled Anandamide[1]. Anandamide is an endocannabinoid. Anandamide modulates both neuronal and immune functions through two protein-coupled cannabinoid receptors (CB1 and CB2). Anandamide can activate numerous other receptors like PPARS, TRPV1, and GPR18/GPR55. Anandamide also has potential anti-fungal and anti-inflammatory activities. Anandamide can be used for the research of Alzheimer’s disease (AD) and ulcerative colitis[2][3][4][5][6].
• Target Antigen: Cannabinoid Receptor; Endogenous Metabolite; Fungal; GPR55; Isotope-Labeled Compounds; PPAR; Tau Protein; TRP Channel
• Type: Isotope-Labeled Compounds
• Related Pathways: Anti-infection;Cell Cycle/DNA Damage;GPCR/G Protein;Membrane Transporter/Ion Channel;Metabolic Enzyme/Protease;Neuronal Signaling;Others;Vitamin D Related/Nuclear Receptor
• Field of Research: Infection
• Purity: 99.90
• Smiles: CCCCC/C([2H])=C([2H])\C/C([2H])=C([2H])\C/C([2H])=C([2H])\C/C([2H])=C([2H])\CCCC(NCCO)=O
• Molecular Weight: 355.58
• References & Citations: [1]Malek N, et al. Anandamide, Acting via CB2 Receptors, Alleviates LPS-Induced Neuroinflammation in Rat Primary Microglial Cultures. Neural Plast. 2015;2015:130639.|[2]Moreira-Silva D, et al. Anandamide Effects in a Streptozotocin-Induced Alzheimer's Disease-Like Sporadic Dementia in Rats. Front Neurosci. 2018 Sep 21;12:653.|[3]Troy-Fioramonti S, et al. Acute activation of cannabinoid receptors by Anandamide reduces gastrointestinal motility and improves postprandial glycemia in mice. Diabetes. 2015 Mar;64(3):808-18.|[4]Sionov RV, et al. Anandamide prevents the adhesion of filamentous Candida albicans to cervical epithelial cells. Sci Rep. 2020 Aug 13;10(1):13728.|[5]Pflüger-Müller B, et al. The endocannabinoid anandamide has an anti-inflammatory effect on CCL2 expression in vascular smooth muscle cells. Basic Res Cardiol. 2020 Apr 22;115(3):34.|[6]Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216.
• Shipping Conditions: Blue Ice
• Storage Conditions: Solution, -20°C, 2 years
• Clinical Information: No Development Reported